| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL (NCT04496349) | Ascentage Pharma Group Inc. | 2021-07-12 |
| Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) (NCT04728893) | Merck Sharp & Dohme LLC | 2021-04-05 |
| To Assess the Safety and Tolerability of Tafasitamab Alone or in Combination With Other Drugs in Japanese Participants With Non-Hodgkins Lymphoma (NHL) (NCT04661007) | Incyte Biosciences Japan GK | 2020-12-15 |
| Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL (NCT04240704) | Novartis Pharmaceuticals | 2020-09-07 |
| Resiliency in Older Adults Undergoing Bone Marrow Transplant (NCT04188678) | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 2018-09-28 |
| Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies (NCT03465540) | Amgen | 2018-08-17 |
| An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NCT03533283) | Hoffmann-La Roche | 2018-05-08 |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer (NCT02391480) | AbbVie | 2015-04-14 |
| Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma (NCT02110563) | Dicerna Pharmaceuticals, Inc., a Novo Nordisk company | 2014-04-01 |
| 3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma (NCT02057445) | New York Medical College | 2014-01-01 |
| Use of Hyperbaric Oxygen Therapy to Improve Umbilical Cord Blood Stem Cell Homing and Subsequent Engraftment (NCT02099266) | University of Kansas Medical Center | 2013-06-01 |
| Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies (NCT01744912) | TG Therapeutics, Inc. | 2012-11-21 |
| Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL (NCT01659255) | Gilead Sciences | 2012-08-17 |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (NCT01647971) | TG Therapeutics, Inc. | 2012-07-19 |
| Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor (NCT01598025) | Memorial Sloan Kettering Cancer Center | 2012-05-02 |
| Allogeneic Transplantation Using Timed Sequential Busulfan and Fludarabine Conditioning (NCT01572662) | M.D. Anderson Cancer Center | 2012-04-11 |
| Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match (NCT01500161) | Texas Oncology Cancer Center | 2011-11-01 |
| A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma (NCT01290549) | Genentech, Inc. | 2011-03-22 |
| Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma (NCT01281917) | University of Wisconsin, Madison | 2011-02-01 |
| TXA127 in Enhancement of Engraftment in Adult Double Cord Blood Transplantation (NCT01300611) | Tarix Pharmaceuticals | 2011-01-01 |
| Study of the Best Timing for Plerixafor in Autologous Hematopoietic Stem Cell Collection (NCT01042717) | Shi, Patricia, M.D. | 2010-02-01 |
| Intensity Modulated Total Marrow Irradiation (IM-TMI) for Advanced Hematologic Malignancies (NCT00988013) | University of Illinois at Chicago | 2009-09-01 |
| Pilot Trial of Targeted Immune-Depleting Chemotherapy and Reduced-Intensity Matched Unrelated Double Cord Blood Transplant for the Treatment of Leukemias, Lymphomas, and Pre-Malignant Blood Disorders (NCT00973804) | National Cancer Institute (NCI) | 2009-08-25 |
| Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant (NCT00901225) | Duke University | 2009-05-01 |
| A Phase 1 Dose Escalation Study of TAK-901 in Subjects With Advanced Hematologic Malignancies (NCT00807677) | Millennium Pharmaceuticals, Inc. | 2009-03-01 |
| Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies (NCT00837200) | Milton S. Hershey Medical Center | 2009-03-01 |
| Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma (NCT00856245) | University of Kansas Medical Center | 2009-02-01 |
| Safety of SGI-1776, A PIM Kinase Inhibitor in Refractory Prostate Cancer and Relapsed/Refractory Non Hodgkin's Lymphoma (NCT00848601) | Astex Pharmaceuticals, Inc. | 2009-02-01 |
| Brown Fat Activity and White Fat Accumulation (NCT01517581) | Children's Hospital Los Angeles | 2008-10-01 |
| Blood Samples to Evaluate Biomarkers of Donor Chimerism (NCT00764829) | Fred Hutchinson Cancer Center | 2008-09-01 |
| Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma (NCT00807196) | Maisonneuve-Rosemont Hospital | 2008-09-01 |
| Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies. (NCT00739141) | Memorial Sloan Kettering Cancer Center | 2008-08-12 |
| The Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients (NCT00726934) | Indiana University | 2007-09-01 |
| A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer. (NCT00432562) | Mast Therapeutics, Inc. | 2007-02-01 |
| Aurora Kinase Inhibitor AT9283 in Treating Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma (NCT00443976) | NCIC Clinical Trials Group | 2007-01-30 |
| Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease (NCT00364676) | Spectrum Pharmaceuticals, Inc | 2006-07-01 |
| Compassionate Use of Erwinase For Pediatric Patients With Acute Lymphoblastic Leukemia Or Non Hodgkins Lymphoma (NCT00693602) | St. Jude Children's Research Hospital | 2006-06-01 |
| Intensive Chemotherapy and Rituximab in the Treatment of Burkitt Lymphoma (NCT00126191) | Dana-Farber Cancer Institute | 2005-07-01 |
| Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma (NCT00179673) | Celgene | 2005-06-01 |
| Irinotecan, Vincristine, and Dexamethasone In Children With Relapsed And/Or Refractory Hematologic Malignancies (NCT00718757) | St. Jude Children's Research Hospital | 2005-01-01 |
| Biology Studies of Hematologic Cancers (NCT00923442) | National Cancer Institute (NCI) | 2004-02-24 |
| Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma (NCT00193505) | SCRI Development Innovations, LLC | 2003-10-01 |
| Combination Chemotherapy and Rituximab With Pegfilgrastim Followed by Rituximab, in Large B-Cell Non-Hodgkin's Lymphoma (NCT00193479) | SCRI Development Innovations, LLC | 2003-04-01 |
| Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma (NCT00051701) | Genzyme, a Sanofi Company | 2002-12-01 |
| Safety Study of NHL With 90Y-hLL2 IgG (NCT00421395) | Gilead Sciences | 2002-08-01 |
| Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma (NCT00193440) | SCRI Development Innovations, LLC | 2002-04-01 |
| Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (NCT00193466) | SCRI Development Innovations, LLC | 2002-01-01 |
| CHOP/Rituximab Followed by Maintenance PEG Intron in Treatment of Indolent/Follicular Non-Hodgkin's Lymphoma (NCT00574730) | University of Nebraska | 2001-05-23 |
| Safety and Efficacy of Pentostatin and Low Dose TBI With Allogenic Peripheral Blood Stem Cell Transplant (NCT00571662) | University of Nebraska | 2000-12-08 |
| T Cell Depletion for Recipients of HLA Haploidentical Related Donor Stem Cell Grafts (NCT00368355) | Baylor College of Medicine | 2000-04-01 |
| Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (NCT00091676) | Biovest International | 2000-01-01 |
| Antineoplaston Therapy in Treating Patients With High-Grade Stage II - Stage IV Non-Hodgkin's Lymphoma (NCT00003501) | Burzynski Research Institute | 1996-04-10 |
| Antineoplaston Therapy in Treating Patients With Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma (NCT00003500) | Burzynski Research Institute | 1996-03-11 |
| Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (NCT00058773) | Baylor College of Medicine | 1996-01-01 |
| Treatment and Natural History Study of Lymphomatoid Granulomatosis (NCT00001379) | National Cancer Institute (NCI) | 1995-05-05 |
| A Retrospective Review of Gemcitabine, Methylprednisolone Cisplatin (GEM-P) With or Without Rituximab in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL) (NCT00301301) | Royal Marsden NHS Foundation Trust | |
| A Retrospective Study of Toxicity and Outcome of High Dose Chemotherapy With Autologous Stem Cell Transplant in Patients With Non-Hodgkin Lymphoma (NHL). (NCT00301288) | Royal Marsden NHS Foundation Trust | |